M G E H Lam

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. ncbi Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
    Maarten L J Smits
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, E01, 132, 3584 CX Utrecht, The Netherlands
    J Exp Clin Cancer Res 29:70. 2010
  2. ncbi Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP
    M G E H Lam
    University Medical Center Utrecht, Department of Nuclear Medicine, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Nuklearmedizin 48:37-43. 2009
  3. ncbi Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined
    Marnix G E H Lam
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands
    J Palliat Med 12:649-51. 2009
  4. ncbi Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases
    M G E H Lam
    University Medical Center Utrecht, Department of Nuclear Medicine, Utrecht, The Netherlands
    Anticancer Agents Med Chem 7:381-97. 2007
  5. ncbi Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
    Marnix G E H Lam
    Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur J Nucl Med Mol Imaging 35:756-65. 2008
  6. ncbi (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study
    Marnix G E H Lam
    Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1425-33. 2009
  7. ncbi Technical solutions to ensure safe yttrium-90 radioembolization in patients with initial extrahepatic deposition of (99m)technetium-albumin macroaggregates
    M W Barentsz
    Center of Interventional Oncology and Department of Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Cardiovasc Intervent Radiol 34:1074-9. 2011
  8. ncbi 186Re-HEDP for metastatic bone pain in breast cancer patients
    Marnix G E H Lam
    Department of Nuclear Medicine, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Eur J Nucl Med Mol Imaging 31:S162-70. 2004
  9. ncbi Bone mineral density in children with moderate to severe atopic dermatitis
    Sara Gertrudes Anna Van Velsen
    Department of Dermatology and Allergology, Wilhelmina s Children s Hospital, University Medical Center Utrecht, The Netherlands
    J Am Acad Dermatol 63:824-31. 2010
  10. ncbi Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis
    M A D Vente
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur Radiol 19:951-9. 2009

Collaborators

Detail Information

Publications13

  1. ncbi Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
    Maarten L J Smits
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, E01, 132, 3584 CX Utrecht, The Netherlands
    J Exp Clin Cancer Res 29:70. 2010
    ..Previous studies have demonstrated the safety of 166Ho-PLLA-MS radioembolization ( 166Ho-RE) in animals. The aim of this phase I trial is to assess the safety and toxicity profile of 166Ho-RE in patients with liver metastases...
  2. ncbi Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP
    M G E H Lam
    University Medical Center Utrecht, Department of Nuclear Medicine, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Nuklearmedizin 48:37-43. 2009
    ..The aim of this prospective study was the investigation of radiation safety after treatment with these radiopharmaceuticals. The radiation field around treated patients was characterized and the magnitude estimated...
  3. ncbi Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined
    Marnix G E H Lam
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands
    J Palliat Med 12:649-51. 2009
    ..No negative interaction was found, toxicity was low, and efficacy high. He experienced a total relief of pain, a significant decrease of prostate-specific antigen (PSA) and, surprisingly, a significant decrease of tumor burden...
  4. ncbi Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases
    M G E H Lam
    University Medical Center Utrecht, Department of Nuclear Medicine, Utrecht, The Netherlands
    Anticancer Agents Med Chem 7:381-97. 2007
    ..Additionally, new therapeutic strategies hold the promise of enhancement of the palliative and anticancer effects of this form of therapy...
  5. ncbi Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
    Marnix G E H Lam
    Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur J Nucl Med Mol Imaging 35:756-65. 2008
    ..Because of the different therapeutic effects, combining the treatments may be beneficial. Both, however, accumulate in areas with increased osteoblastic activity. Possible drug interactions were investigated...
  6. ncbi (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study
    Marnix G E H Lam
    Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1425-33. 2009
    ..Efficacy may be improved by adding chemotherapy to the treatment regimen as a radiation sensitizer. The combination of (188)Re-HEDP and capecitabine (Xeloda(R)) was tested in a clinical phase I study...
  7. ncbi Technical solutions to ensure safe yttrium-90 radioembolization in patients with initial extrahepatic deposition of (99m)technetium-albumin macroaggregates
    M W Barentsz
    Center of Interventional Oncology and Department of Radiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    Cardiovasc Intervent Radiol 34:1074-9. 2011
    ....
  8. ncbi 186Re-HEDP for metastatic bone pain in breast cancer patients
    Marnix G E H Lam
    Department of Nuclear Medicine, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Eur J Nucl Med Mol Imaging 31:S162-70. 2004
    ..It has been associated with marked pain reduction, improved mobility in many patients, reduced dependence on analgesics, and improved performance status and quality of life...
  9. ncbi Bone mineral density in children with moderate to severe atopic dermatitis
    Sara Gertrudes Anna Van Velsen
    Department of Dermatology and Allergology, Wilhelmina s Children s Hospital, University Medical Center Utrecht, The Netherlands
    J Am Acad Dermatol 63:824-31. 2010
    ..Low bone mineral density (BMD) has been reported in 30.4% of adult patients with atopic dermatitis (AD)...
  10. ncbi Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis
    M A D Vente
    Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur Radiol 19:951-9. 2009
    ..In HCC, (90)Y-RE with resin microspheres is significantly more effective than (90)Y-RE with glass microspheres. The impact on survival will become known only when the results of phase III studies are published...
  11. ncbi The influence of diffuse idiopathic skeletal hyperostosis on bone mineral density measurements of the spine
    L Anneloes Westerveld
    Department of Orthopaedics, University Medical Center Utrecht, Utrecht, The Netherlands
    Rheumatology (Oxford) 48:1133-6. 2009
    ..The contribution of the ossified anterior longitudinal ligament (ALL) on vertebral body BMD is currently unknown. We investigated the influence of DISH on BMD measurements using an experimental DXA scanning protocol...
  12. ncbi Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma
    Marnix G E H Lam
    University Medical Center Utrecht, Department of Nuclear Medicine, P O Box 85500, 3508 GA Utrecht, The Netherlands
    J Clin Endocrinol Metab 90:5888-95. 2005
    ..We present our experience with multiple intermediate-dosage [131I]MIBG therapy instead of single high-dosage therapy...
  13. ncbi Re: does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Marnix G E H Lam
    J Nucl Med 46:2118; author reply 2118-9. 2005